Skip to main content

Peer Review reports

From: Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

Original Submission
21 Jul 2023 Submitted Original manuscript
20 Oct 2023 Reviewed Reviewer Report
14 Dec 2023 Reviewed Reviewer Report
16 Dec 2023 Reviewed Reviewer Report
2 Feb 2024 Author responded Author comments - Li Xu
Resubmission - Version 2
2 Feb 2024 Submitted Manuscript version 2
13 Feb 2024 Reviewed Reviewer Report
14 Feb 2024 Reviewed Reviewer Report
11 Mar 2024 Author responded Author comments - Li Xu
Resubmission - Version 3
11 Mar 2024 Submitted Manuscript version 3
Publishing
14 Mar 2024 Editorially accepted
23 Apr 2024 Article published 10.1186/s12916-024-03356-5

You can find further information about peer review here.

Back to article page